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Cell death, apoptosis, ischemia/reperfusionIschemia/reperfusion injury is a major cause of myocardial death. In the heart, cardiac ﬁbroblasts play a
critical role in healing post myocardial infarction. TGF-β1 has shown cardioprotective effects in cardiac dam-
age; however, if TGF-β1 can prevent cardiac ﬁbroblast death triggered by ischemia/reperfusion is unknown.
Therefore, we test this hypothesis, and whether the canonical and/or non-canonical TGF-β1 signaling
pathways are involved in this protective effect. Cultured rat cardiac ﬁbroblasts were subjected to simulated
ischemia/reperfusion. Cell viability was analyzed by trypan blue exclusion and propidium iodide by ﬂow
cytometry. The processing of procaspases 8, 9 and 3 to their active forms was assessed by Western blot,
whereas subG1 population was evaluated by ﬂow cytometry. Levels of total and phosphorylated forms of
ERK1/2, Akt and Smad2/3 were determined by Western blot. The role of these signaling pathways on the
protective effect of TGF-β1 was studied using speciﬁc chemical inhibitors. Simulated ischemia over 8 h trig-
gers a signiﬁcant cardiac ﬁbroblast death, which increased by reperfusion, with apoptosis actively involved.
These effects were only prevented by the addition of TGF-β1 during reperfusion. TGF-β1 pretreatment in-
creased the levels of phosphorylated forms of ERK1/2, Akt and Smad2/3. The inhibition of ERK1/2, Akt and
Smad3 also blocked the preventive effects of TGF-β1 on cardiac ﬁbroblast apoptosis induced by simulated
ischemia/reperfusion. Overall, our data suggest that TGF-β1 prevents cardiac ﬁbroblast apoptosis induced
by simulated ischemia–reperfusion through the canonical (Smad3) and non canonical (ERK1/2 and Akt) sig-
naling pathways.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ischemia and reperfusion (I/R) injury is a major cause of myo-
cardial death. Ischemia causes extensive biochemical changes in the
cytoskeleton and subcellular organelles, leading to the cell death [1].
Although reperfusion initially restores cardiac tissue function, provid-
ing nutrients and oxygen to deprived ischemic tissue, and limits the
extent of myocardial necrosis [2], this process also may induce addi-
tional cell death associated to the generation of reactive oxygen species
(ROS), producing oxidative modiﬁcation and proteolysis of several pro-
teins [3–5]. I/R trigger necrosis and apoptosis depending on the intensi-
ty and time duration of injury. The latter type of cell death is especially
important during the reperfusion stage [6].as y Farmacéuticas, Universidad
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l rights reserved.Cardioprotective effects of TGF-β1 have been widely reported
[7–9]. TGF-β1 binds to speciﬁc receptors with serine–threonine ki-
nase activity, leading to intracellular signaling through the activation
of the canonical pathway Smad 2/3 [10]. However, TGF-β1 also
signals through the non-canonical signaling pathways, including
ERK1/2 and PI3K-Akt [11–13]. In rat cardiac ﬁbroblasts (CFs), the
activation of TGF-β1-dependent Smad2/3 pathway positively corre-
lated with ﬁbrosis. This growth factor promotes the secretion of ex-
tracellular matrix (ECM) proteins, as well as the CF differentiation
to cardiac myoﬁbroblasts [14,15]. In CF, the activation of ERK1/2,
PI3K-Akt and Smad2/3 by TGF-β1 is linked to increased lysyl oxidase
expression, a key enzyme controlling cardiac ﬁbrosis [16]. However,
TGF-β1-dependent ERK1/2 and PI3K-Akt signaling pathways can
mediate the proapoptotic effects in epithelial cells or anti-apoptotic
actions in neuronal and osteoclast cells [17–19].
CFs are themajor non-myocyte cell constituent in themyocardium
and actively participate in the maintenance of myocardial structure
by controlling the homeostasis of the ECM in normal tissue, but they
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secretion of cytokines, growth factors and metalloproteases [20]. De-
spite the extensive literature on the effects of I/R on cardiac myocytes,
studies on the effects of I/R in CF death are scarce, as well as how
TGF-β1 could exert its cardioprotective effect [21]. In the present
work we determine the effect of simulated I/R (sI/R) on CF death by
apoptosis and/or necrosis; as well as to identify the signaling path-
ways activated by this cytokine to exert its cytoprotective effect on
CF death. We hypothesize that TGF-β1 through the canonical and
noncanonical signaling pathways prevents CF apoptosis induced by
sI/R.2. Methods
2.1. Reagents
The following reagents were from Sigma Chemical Co (St. Louis,
MO, USA): trypan blue and PD98059 (PD); from Gibco BRL (Carlsbad,
CA, USA): primary antibody for β-tubulin, trypsin/EDTA, pre-stained
molecular weight standards, fetal bovine serum (FBS) and fetal calf
serum (FCS). All organic and inorganic compounds were from Merck
(Darmstadt, Germany). The enhanced chemo-luminescence reagent
was from Perkin Elmer Life Sciences, Inc. (Boston, MA, USA). TGF-β1
was from Millipore (Billerica, MA, USA). The primary antibodies for
caspases 9, 8 and 3, ERK1/2, p-ERK1/2, Akt, p-Akt, p-Smad2, Smad2,
p-Smad3 and Smad3 were from Cell Signaling Technology (Boston,
MA, USA), LY294002 (LY) was from Cayman Chemicals (Ann Arbor,
MI, USA). Secondary antibodies, TGF-β1 signaling pathway inhibitors
were from Sigma-Aldrich: PD for ERK1/2, SB431542 (SB) (inhibitor
TβR1-Smad2/3), SIS3 for smad3, LY for PI3K-Akt and Akti for Akt.2.2. Isolation and culture of cardiac ﬁbroblasts
Rats were obtained from the Animal Breeding Facility of the Facul-
ty of Chemical and Pharmaceutical Sciences, University of Chile. All
studies were conformed the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publi-
cation No. 85-23, revised 1996) and experimental protocols were
approved by our Institutional Ethics Review Committee. Neonate rat
CFs were isolated from the ventricles of 1–3 day-old Sprague–Dawley
rats as described previously [22]. In brief, ventricles were minced and
digested in 0.05% collagenase (Gibco, Invitrogen, Carlsbad, CA, USA)
and 0.05% pancreatin (Sigma, St. Louis, MO, USA) containing solution
at 37 °C. The digestion yield was pre-cultured for 2 h at 37 °C in cul-
ture media containing 5% FBS and 10% FCS. Differential adhesion on
plastic allows the isolation of CF from cardiac myocytes. After 2 h, cul-
ture media was replaced for DMEM-F12 containing 10% FBS media
and CFs were let to proliferate to conﬂuence. Cellular passages were
performed using 0.05% trypsin/EDTA (passage 2 as maximum). After
passage 2, cultures were maintained with DMEM-F12.2.3. Simulated ischemia/reperfusion protocol
CFs were maintained for 24 h in DMEM-F12, and then they were
washed with phosphate buffer saline (PBS) before ischemic protocol.
The cells were exposed to a balanced salt solution (ischemicmedium),
(composition in mM: NaCl 115, KCl 12, MgCl2 1.2, CaCl2 2, HEPES 25,
lactic acid 20 mM and 2-deoxy-D-glucose 20 mM), for different times.
Hypoxia was achieved in a customized chamber by N2 ﬂow at 37 °C. A
reperfusion protocol was developed replacing the ischemic medium
with DMEM-F12 in a 95/5% air/CO2 incubator (37 °C) for the indicated
times. Control (C) cells were incubated in DMEM F-12 for different
ischemia times in a 95/5% air/CO2 incubator.2.4. Cell viability
CF cultures with a 2×104 cells/mm2 density in 35 mm plastic
dishes in DMEM-F12 media were stimulated under the conditions in-
dicated for each experiment. After the stimulation, cells were treated
with trypsin/EDTA 1× for detachment and the action of this protease
was inhibited by adding DMEM-F12 plus 10% FBS. After detachment,
a 20 μL aliquot plus 20 μL of trypan bluewere transferred to a Neubauer
camera and cell counting was performed by microscopy. Experiments
were performed in triplicate and repeated ﬁve times. At least 400 cells
were counted in each well.
2.5. SubG1 determination by ﬂow cytometry
After treatment, cells were collected, permeabilized with ice-
methanol overnight, and treated with RNAase in PBS for 1 h, and 3 μL
propidium iodide was included before ﬂow cytometry (PI, 25 mg/mL).
Finally, the DNA fragmentation (sub-population G1) was determined
by ﬂow cytometry analysis. A total of 5000 cells/sample were analyzed.
2.6. Western blot analysis
50 μg of total protein extracts was separated by SDS-PAGE. Then,
proteins were electrotransferred to a PVDF membrane, which was
blocked with non-fat milk 5% (w/v). Antibodies against p-ERK1/2,
p-Akt, p-Smad2, p-Smad3, caspases 3, 8 and 9 (dilution 1:1,000) or
tubulin (dilution 1:10,000) were incubated overnight at 4 °C. Second-
ary antibody (dilution 1:5,000), was incubated for 2 h at room tem-
perature. After washing, membranes were exposed to enhanced
chemoluminiscent (ECL) reagent. BioMax ﬁlm was used for western
blot determinations. Blots were quantiﬁed by laser scanning densi-
tometry. Total ERK, Akt, Smad2, Smad3 and tubulin antibodies were
used to control equal loading of all blots.
2.7. Immunoﬂuorescence studies
CFs were seeded onto coverslips in six-well cell culture dishes and
were then serum starved by washing twice with PBS, adding starva-
tion media, and incubating for 24 h. After the cells were washed
with PBS and ﬁxed with 4% paraformaldehyde for 10 min. Cells were
thenwashed three timeswith PBS and permeabilizedwith 0.1% Triton
X-100 followed by three additional washes. Slides were blocked with
3% bovine serum albumin in PBS for 30 min, washed, and incubated
overnight with primary antibody (Smad2) diluted in 1% BSA in PBS.
Again, cells were washed three times with PBS and incubated with
Alexa Fluor-conjugated secondary antibody for 1.5 h followed by
another wash cycle. Coverslips were dried, using a vacuum, and
mounted on slides using Dako with Hoechst mounting media and
then sealed with nail polish. The ﬁnal images were obtained by confo-
cal microscopy.
2.8. Necrosis by ﬂow cytometer
Cells were collected, centrifuged at 1500 rpm for 5 min and the sol-
uble fraction recovered and kept on ice. Cells remaining on the plates
(live cells) were released dilution with 0.3 mL of 1× trypsin-EDTA in
PBS (37 °C). Immediately, the cells were added propidium iodide (PI).
Finally cellular necrosiswas determined by the incorporation of necrotic
cardiac ﬁbroblast IP ﬂow cytometry (FACS CANTO, Becton Dickinson).
2.9. LDH activity
After completion of the experimental time 500 μL collected
DMEM-F12 from each well and stored at−20 °C for subsequent anal-
ysis. The disappearance of the absorbance of NADH (10 mg/mL) in
the presence of lactate (2.5 mg/mL), phosphate buffer (pH 7.0) and
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2 min at a temperature of 37 °C. After which the enzymatic activities
were obtained (AAbs/min). The obtained values are interpolated on a
calibration curve previously designed, which relates the LDH enzyme
activity with the number of necrotic cells.
2.10. Statistical analysis
All data are presented as means 4–8 independent experiments
±S.E.M. The differences in each parameter were evaluated by a one-
way ANOVA of the increase or decrease of each variable measured.
One-way ANOVA was followed by the Tukey test to compare the effect
of different conditions on these parameters. Statistical signiﬁcance was
accepted at Pb0.05.
3. Results
3.1. I/R induces CF death by apoptosis
Ischemia is a major damaging event affecting cardiac cells. Fig. 1A,
shows that simulated ischemia induces the loss of CF viability in aCA
B
D
Fig. 1. Deleterious effects of ischemia and I/R in cardiac ﬁbroblasts. Time course of loss of via
(B) (**pb0.01 and ***pb0.001 vs I 8 h, n=6), as measured by the quantiﬁcation of trypan b
9, 8 and 3 (**pb0.01 and ***pb0.001 vs C/I, #pb0,05 and ##pb0.001 vs I 8 h. n=6). (D) Grap
ischemia (8 h) and I/R (8 h/24 h) (***pb0.001 vs I 8 h). The results are means (±S.E.M.) otime-dependent manner, being signiﬁcant from 12 h. For reperfusion
studies, 8 h of ischemia was chosen because there are no changes in
cell viability at this time. Fig. 1B shows that reperfusion by 16, 24
and 48 h induces the loss of CF statistically signiﬁcant of simulated
ischemia (8 h), and peaking at 48 h. The injurious effect caused by
reperfusion was mediated primarily through apoptosis. The main
players of the apoptotic program are caspases. Fig. 1C depicts that
simulated ischemia (8 h) induces caspases 9 and 3 activation, but
not in caspase 8. However, reperfusion signiﬁcantly activated these
three caspases. Also in Fig. 1D we show by DNA fragmentation
(sub-population G1), that simulated ischemia (8 h) does not induce
apoptosis; however, reperfusion (8/24 h) induces a signiﬁcant apo-
ptosis. Supplementary Fig. 1 shows that simulated ischemia (24 h) in-
duces CF death over 80%, whereas that sI/R (8/16; and therefore a
total time of 24 h), CF death was approximately 37%. Supplementary
Fig. 2A shows that simulated ischemia (8 h) does not produce necrosis;
whereas reperfusion induced necrosis from 24 h with respect to the
control (CI), control of reperfusion (C/R) and simulated ischemia (sI).
Simulated ischemia (8 h) did not increase the release of LDH into the
extracellular medium; whereas reperfusion produced a signiﬁcant re-
lease of LDH into the extracellularmedium (see Supplementary Fig. 2B).51 KDa
38 KDa
57 KDa
43 KDa
35 KDa
17 KDa
55 KDa
bility in cardiac ﬁbroblasts subjected to ischemia (A) (***pb0.001 vs C/I, n=6) and I/R
lue exclusion. (C) Densitometry of representative immunoblot of activation of caspases
hic analysis of apoptosis measured by ﬂow cytometry in cardiac ﬁbroblasts undergoing
f 6 independent experiments.
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To test cytoprotective effect of TGF-β1, CFs were subjected to sI/R
in the presence or absence of TGF-β1 (5 ng/mL). Incubation with
TGF-β1 for the entire period of sI/R (8 h/24 h), induced signiﬁcant
protection against the loss of cell viability (Fig. 2A), as well as apopto-
sis (Fig. 2C). On the other hand, simulated ischemia (8 h) triggers the
processing of procaspases 9 and 3 but not caspase 8 (Fig. 2B), which
was not prevented by TGF-β1. Additionally, reperfusion signiﬁcantly
triggers caspases 8, 9 and 3 fragmentations, effects which were atten-
uated by TGF-β1. This cytokine alone did not induce caspase fragmen-
tation during simulated ischemia.
In order to analyze whether the cytoprotective effect of TGF-β1
takes place during simulated ischemia, reperfusion, or sI/R; experi-
ments were conducted according to the scheme shown in Fig. 3A.
Incubation with TGF-β1 during simulated ischemia alone (+/−) did
not induce protection in the loss of cell viability (Fig. 3B), caspase 3
fragmentation (Fig. 3C) or apoptosis (Fig. 3D) compared with sI/R.
TGF-β1 addition during reperfusion (−/+) or sI/R (+/+) stimulated
a signiﬁcant protection in the loss of CF viability (Fig. 3B), apoptosis
(Fig. 3C) and procaspase 3 fragmentation (Fig. 3D) compared to sI/R.
Finally, we test the effects of TGF-β1 in adult rat CF (Supplementary
Fig. 3), and we show a similar cell behavior against sI/R injury; and
similarly, TGF-β1 shows cytoprotective effects similar to those ob-
served in neonatal CF against sI/R.A
C
Fig. 2. TGF-β1 promotes cytoprotection in cardiac ﬁbroblasts subject to I/R. TGF-β1 (TGF: 5 ng
of trypan blue exclusion (#pb0,05 and ###pb0,001 vs. I 8 h; &&pb0,01 vs. I/R), and (B) the a
sured by the densitometry of representative immunoblots (**pb0.01 vs. C/I, #pb0.05 and ##
triggered in cardiac ﬁbroblasts subject to I/R (8 h/24 h) (**pb0.01 and ***pb0.001 vs. I 8 h, #3.3. TGF-β1 signaling pathways involved in cardiac ﬁbroblast protection
TGF-β1 activates several signaling pathways in CF, including the
canonical (Smad2/3) and non-canonical (ERK1/2 and Akt) pathways.
TGF-β1 activated Smad2/3, ERK1/2 and Akt in normal CF (Supplemen-
tary Fig. 4A–B, respectively). Nextwe studywhether these TGF-β1 sig-
naling pathways were associated with its protective effects. As shown
in Fig. 4A, simulated ischemia (8 h) and reperfusion do not activate
Smad2/3, but TGF-β1 caused a signiﬁcant activation of Smad2/3 dur-
ing reperfusion. In parallel, simulated ischemia (8 h) decreased the
levels of phospho-ERK1/2, but not for Akt (Fig. 4B). A signiﬁcant acti-
vation of both kinases was detected during the ﬁrst 10 min reperfu-
sion with respect to control and ischemia (8 h). However, TGF-β1
treatment for 10 min triggers a higher activation of ERK1/2 and Akt
during reperfusion with respect to sI/R. In addition, TGF-β1 also stim-
ulated a signiﬁcant Akt activation after 24 h compared with sI/R. We
also studied whether these TGF-β1 signaling pathways are activated
in simulated ischemia. Our results (Supplementary Fig. 5), show that
ERK1/2 is activated at 10 min after ischemia starts; however, after 1
and 8 h of ischemia ERK1/2 was inactivated. In the same manner,
simulated ischemia dephosphorylates Akt. However, TGF-β1 did not
have any additional effect on the activation of these signaling path-
ways, although TGF-β1 triggers Smad2 phosphorylation.
Finally, we used speciﬁc inhibitors to investigate the role of these
signaling pathways on CF viability and apoptosis. As shown in Fig. 4C;B
17 KDa
35 KDa
43 KDa
57 KDa
38 KDa
51 KDa
55 KDa
/mL) exerts protection against both (A) cell viability lostmeasured by the quantiﬁcation
ctivation of caspases 9, 8 and 3 produced by I/R (8 h/24 h), but not ischemia (8 h) mea-
#pb0.001 vs. I 8 h, &pb0.05 vs. &&pb0.01 vs. I/R n=6). (C) apoptosis by ﬂow cytometry
#pb0.01 vs. I/R+TGF). The results are means (±S.E.M.) of 6 independent experiments.
AB C
D
17 KDa
35 KDa
55 KDa
Fig. 3. Time course of cytoprotective effects by TGF-β1 in cardiac ﬁbroblast subject to I/R. (A) representative diagram of TGF-β1(TGF: 5 ng/mL) treatment during ischemia (+/−),
only in reperfusion (−/+) and in both instances (+/+). (B) Graphic analysis of cytoprotection afforded by TGF-β1 on loss of cell viability quantiﬁed by trypan blue exclusion,
(C) the activation of caspase 3, measured by the densitometry of representative immunoblots, and (D) apoptosis by ﬂow cytometry (*pb0.05, **pb0.01 and ***pb0.001 vs. C/R,
#pb0.05 and ##pb0.01 vs. I/R). The results are means (±S.E.M.) of 4 independent experiments.
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activated by TGF-β1, and we did not observe cross-modulation of the
inhibitors between these signaling pathways. Supplementary Fig. 6
depicts that Smad2 is localized in the cytosol in unstimulated CF.
However, TGF-β1 (1 h) stimulated Smad2 migration to the nucleus,
being affected by SB but not by PD and LY. As shown earlier, ERK1/2
and Akt, but not Smad2/3, were activated by reperfusion in CF.
Thus, we evaluated whether these protective signaling pathways are
involved in the prevention of CF death after sI/R. To this aim, CFs
were subjected to sI/R in the presence of PD and LY. Both inhibitors
potentiated the injured events caused by sI/R, increasing the loss of
cell viability (Supplementary Fig. 7A), activation of caspases 8, 9 and
3 (Supplementary Fig. 7B) and apoptosis (Supplementary Fig. 7C)
whereas, SB did not change the effects induced by I/R.
Fig. 5A shows that the protection in cell viability, induced by
TGF-β1, was completely blocked by PD, LY and SB. Similar resultswere observed on the activation of caspases 8, 9 and 3 (Fig. 5B) and
apoptosis (Fig. 5C). Finally, we evaluated the role of Akt and Smad3
on the cytoprotective effects triggered by TGF-β1 using the speciﬁc
inhibitors Akti and SIS3. Our results show that both inhibitors
completely prevented the cytoprotective and anti-apoptotic effects
of TGF-β1 (Fig. 6A–B), suggesting that Akt and Smad3 participate in
the cytoprotective effects of TGF-β1.
4. Discussion
The main result of this study was that TGF-β1 activated canonical
and non-canonical signaling pathways and produce cytoprotective
effects on cultured neonate and adult rat CF under sI/R. According to
the literature ischemia causes cell damage in a time dependent man-
ner, as demonstrated both by increased cell death under ischemia in
in vitro assays [23], as well as in in vivo models of cardiac ischemia
A B
C D
p-Smad2
p-Smad2
Smad2
Smad2
p-Smad3
Smad3
p-Smad3
Smad3
p-ERK1/2
ERK1/2
p-ERK1/2
ERK1/2
p-Akt
Akt
p-Akt
Akt
Fig. 4. Activation of ERK1/2, Akt and Smad2/3 signaling pathways by I/R and TGF-β1. I/R and TGF-β1 (TGF: 5 ng/mL) activate the (A) canonical (Smad2 and Smad3) and
(B) non-canonical (ERK1/2 and Akt) signaling pathways, measured by densitometry of representative immunoblots for each protein (*pb0.05, **pb0.01 and ***pb0.001 vs. C/I,
#pb0,05, and ###pb0.001 vs. I/R 10 min; &&pb0.01 and &&&pb0.001 vs. I/R 24 h). The results are means (±S.E.M.) of 8 independent experiments. (C) Representative immuno-
blot of p-ERK1/2, p-Akt and p-Smad2 in cardiac ﬁbroblast subject to I/R plus TGF-β1, in the presence of speciﬁc inhibitors, PD98059 (PD) (25 μM), LY294002 (LY) (10 μM) and
SB431542 (SB) (10 μM) plus DMSO as vehicle (V).
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in vitrowork is far from those performed in vivo; however, several in-
vestigators have shown a relationship between the damage caused by
I/R in vivowith those performed in in vitro assays [21,25,26]. Our data
are in accordance with the previous observations because simulated
ischemia induced signiﬁcant CF death from 12 h. However, Chen et
al. have reported that CF proliferate and become more active under
anoxia [27]. These differences could be explained by differences in
methodology (anoxia vs hypoxia). Our model of simulated ischemia
includes hypoxia, low pH, nutrient deprivation and the inhibition
of glycolysis, making it more deleterious than hypoxia itself. Our
data also show that non-lethal ischemia (less than 8 h) stimulated
the processing of procaspases 9 and 3 but without DNA fragmenta-
tion (Fig. 1C). These data are somewhat contradictory; it could be
explained by the different energy states experienced by cells during
the ischemic period, in which ATP levels do not completely decrease
[23]. Some reports have shown that cells exposed to apoptotic stimu-
lus activated caspase 3, but are unable to activate the ﬁnal stage ofapoptosis (DNA fragmentation and condensation) [23,28]. Reperfu-
sion is a double edged sword because although initially it may
attenuate cell damage generated by ischemia, thereafter this process
may increase cell death [29,30]. Our data show that CF death caused
by simulated ischemia 24 h is higher than those triggered by sI/R
(8 h/16 h); however the reperfusion (by 16 h) also generates addition-
al CF death compared to control and non-lethal simulated ischemia
(Supplementary Fig. 1). Deleterious events generated by reperfusion
are usually attributed to apoptosis [31–34]. Cardiomyocytes exposed
to I/R die by activating both the intrinsic and extrinsic pathways of
apoptosis [35]. In this regard, our data show that simulated ischemia ac-
tivated caspases 3 and 9 but without DNA fragmentation. However, re-
perfusion triggers a robust apoptotic process by activating the intrinsic
(caspase 9), extrinsic (caspase 8) pathways including the executing
caspase 3 and subsequently increasing sub-G1 population. Collectively,
these results suggest that reperfusion could also stimulate the release of
proapoptotic factors involved in the activation of the extrinsic pathway
of apoptosis. However, other types of cell deathwere triggered in the CF
BA
C
35 KDa
17 KDa
51 KDa
38 KDa
57 KDa
43 KDa
55 KDa
Fig. 5. Cytoprotective effects of TGF-β1 by the activation of ERK1/2, PI3K-Akt and Smad2/3 signaling pathways. (A) Cell viability loss measured by the quantiﬁcation of trypan blue
exclusion, (B) the activation of caspases 9, 8 and 3, measured by the densitometry of representative immunoblots and, (C) apoptosis by ﬂow cytometry in cardiac ﬁbroblast subject to
I/R (8 h/24 h) in the presence of TGF-β1 (5 ng/mL) plus the speciﬁc inhibitors of ERK1/2 (PD: 25 μM), PI3K-Akt (LY: 10 μM) and Smad2/3 (SB: 10 μM) signaling pathways (*pb0.05,
**pb0.01 and ***pb0.001 vs. C/R, #pb0.05 and ##pb0.01 vs. I/R, &pb0.05, &&pb0.01 and &&&pb0.001 vs. I/R+TGF). The results are means (±S.E.M.) of 6 independent experiments.
760 R. Vivar et al. / Biochimica et Biophysica Acta 1832 (2013) 754–762subjected to sI/R. Our data also showed sI/R induced necrosis assessed
by two independent techniques (Supplementary Fig. 2A and B).
It is well known that TGF-β1 promotes CF proliferation and clearly
its differentiation to myoﬁbroblast [36]. We show here that TGF-β1
also exerted cytoprotective effects rather than proliferative actions on
stressed neonate (Supplementary Fig. 8) and adult rat CF. At cardiac
level, TGF-β1 has shown to exert anti-apoptotic effects both in vitroFig. 6. TGF-β1 activates Akt and Smad3 to prevent the loss of CF viability and apoptosis I/R-ind
(B) apoptosis measured by ﬂow cytometry of cardiac ﬁbroblasts subject to I/R (8 h/24 h) trea
and Smad3 (SIS3: 1 μM), respectively (*pb0.05, **pb0.01 and ***pb0.001 vs. C/R; #pb0.05, #
The results are means (±S.E.M.) of 6 independent experiments.[7–9] and in vivo [37]. In CF subjected to sI/R, TGF-β1 decreased the
activation of the intrinsic and extrinsic apoptotic pathways. Several
evidences have shown that TGF-β1 decreases and/or inactivates some
key pro-apoptotic proteins such as Bax and caspaseswhereas in parallel
this growth factor induces anti-apoptotic protein like Bcl-2 [9,17,18].
TGF-β1 may also promote cell survival by preventing the release of
TNF-α [38], a cytokine involved in the activation of caspases 8 and 3uced. (A) Cell viability lossmeasured by the quantiﬁcation of trypan blue exclusion and,
ted with TGF-β1 (5 ng/mL) in the presence of speciﬁc inhibitors of Akt (Akti1/2: 50 μM)
#pb0,01 and ###pb0.001 vs. I/R, &pb0.05, &&pb0.01 and &&&pb0.001 vs. I/R+TGF).
761R. Vivar et al. / Biochimica et Biophysica Acta 1832 (2013) 754–762[39]. Our results depicted that the non-lethal simulated ischemia-
dependent activation of caspases 9 and 3 was not prevented by
TGF-β1. These results suggest that TGF-β1 is not enough to counteract
the damage triggered by a prolonged simulated ischemia. In this regard,
some maneuvers like cardiac preconditioning reduce cardiac damage
produced by ischemia [40–42], but a previous window of time is re-
quired to prevent cardiac damage. In this sense, our results show that
TGF-β1 may also require time to exert cytoprotection. Future work
should explore if TGF-β1 regulates CF survival stimulating gene tran-
scription by the activation of Smad3.
Our results are the ﬁrst to demonstrate that phospho-ERK1/2
levels decreased in CF subjected to simulated ischemia (8 h), while no
changes in the levels of phospho-Akt and phospho-Smad2/3 were
observed. In this sense, our results agree with literature because the
exposure of cardiomyocytes to ischemia also decreased MAPK and Akt
activities [43]. In addition, our results show that ERK1/2 was activated
early at the beginning of simulated ischemia, perhaps as a consequence
of trigger survival mechanism induced by ischemic conditions, whereas
Akt was inactivated during all ischemic period. Thus, the late inactiva-
tion of ERK1/2 and Akt is probably indicating that cell death mecha-
nisms were activated. However, other groups have shown that the
ischemia increased the activation level of ERK1/2 and Akt in cultured
cardiomyocytes [44]. On the other hand, reperfusion increased the acti-
vation of salvage kinases such as ERK1/2 and Akt and maneuvers of
survival in sI/R, such as pre- and post-conditioning, signiﬁcantly acti-
vate all these pathways [45,46]. Our results show that cytoprotective
activity of ERK1/2 and Akt was increased in reperfused CF. Other au-
thors have highlighted the importance of the activation of these survival
pathways as well as their inhibition at the time of reperfusion may
exacerbate damage caused by sI/R. In this sense, Yue et al., showed
that reperfusion of infarcted rat hearts in the presence of inhibitor PD,
increases damage caused by I/R [47]. Our data demonstrate that the
inhibition of ERK1/2, induced greater activation of extrinsic and intrin-
sic pathways of apoptosis, and it has been described in the literature
that caspases are inhibited by survival proteins such as ERK1/2 [48].
Similarly, the presence of the inhibitor LY potentiated the CF apoptosis
effects of sI/R. In this regard, there are several mechanisms by which
Akt could be inhibiting apoptosis, including their ability to inhibit pro-
apoptotic protein Bad and inhibition of the fragmentation of caspase 9
[49,50].
As discussed above, TGF-β1 and reperfusion activated ERK1/2 and
Akt signaling pathways, suggesting that these pathways are partially
involved in the survival mechanism activated by both reperfusion
and TGF-β1. However, under ischemic conditions TGF-β1 does not
triggers ERK1/2 and Akt activation, although Smad2 was activated.
We do not know why under ischemic conditions this growth factor
does not induce the activation of ERK1/2 and Akt; however, we believe
that ischemic conditions (hypoxia, low pH, nutrient deprivation and
inhibition of glycolysis), could hamper the activation of these kinases,
or probably under ischemic conditions the speciﬁc phosphatases are
activated. These studies will be performed further.
On the other hand, in the presence of PD and LY, the anti-apoptotic
effects of TGF-β1 were prevented and they agree with results ob-
served in the cells of neuronal origin [17]. In CF, Smad2/3 regulates
collagen secretion and differentiation to cardiac myoﬁbroblasts [14].
However, our results show for the ﬁrst time that Smad2/3 has
cytoprotective effects on CF subjected to I/R. It is also known that
PI3K-Akt signaling pathway activated through TGF-β1receptor type
1 (TβR1) may have other downstream targets of Akt, including cAbl
[51,52]. However, Akti completely inhibited the cytoprotective effects
of TGF-β1, showing that Akt is involved in CF survival exposed to sI/R.
Finally, SIS3 signiﬁcantly inhibited anti-apoptotic effects of TGF-β1 on
CF under sI/R, showing that Smad3 is important for the cytoprotective
effects of TGF-β1. SIS3 had similar effects to that produced by SB;
therefore, the activation of Smad2/3 is crucial for cytoprotection of
TGF-β1 in sI/R. Although we cannot conclude that Smad2 is directlyinvolved in the anti-apoptotic action of TGF-β1, most of the genes
regulated by the TGF-β1 canonical pathway require both Smad2 and
Smad3 [14,53], and has been shown that Smad2 may have a role in
the effects of both pro- and anti-apoptotic TGF-β1 in cancer cells
[54]. Finally, it has been shown that TGF-β1 modulates cross-talk be-
tween ERK1/2 and Akt with Smad2/3 signaling pathways, suggesting
that maybe the activation of these pathways together could account
for its cytoprotective effect. However, with our results, we suggest
that these pathways play independent cytoprotective roles, since the
speciﬁc activation of Smad2/3 by TGF-β1 was inhibited only by SB
and not by speciﬁc inhibitors of ERK1/2 and Akt.
The main limitation of this work was that: TGF-β1 through TβR1
may activate other signaling pathways apart from Smad2/3, ERK1/2
and Akt, such as p38 or JNK, which have proven to be both pro-
apoptotic and anti-apoptotic [23,55]. This question should be resolved
in further studies.
In conclusion, CF subjected to simulated ischemia and sI/R experi-
enced a loss of viability and apoptosis in a time dependent manner,
although sI/R resulted in additional cell death and apoptosis than
that produced by ischemia alone. Cytoprotective effects of TGF-β1
were mediated by the activation of ERK1/2, Akt and Smad2/3 signal-
ing pathways.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.02.004.
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